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Abstract
Coronary stent implantation is currently performed in > 80%
of percutaneous coronary interventions. Its main late compli-
cation is the development of in-stent restenosis (ISR), occur-
ring in 10–80% of lesions treated in daily practice. The classifi-
cation by Mehran et al. is most commonly used. Current thera-
peutic options to treat ISR include repeat balloon angioplasty,
repeat stenting, cutting balloon angioplasty, directional coro-
nary atherectomy, rotational coronary atherectomy, bra-
chytherapy, and drug-eluting stents (DES).
Klassifikation und gegenwärtige Behandlungsmöglichkeiten der In-Stent-Restenose: Gegenwärtiger Stand
und zukünftige Entwicklungen
Zusammenfassung
Bei Koronarinterventionen wird heute in über 80% eine Stent-
implantation vorgenommen.  Unter Alltagsbedingungen ist
ihre häufigste Spätkomplikation die Entwicklung einer In-
Stent-Restenose (ISR) in 10–80%. Die Klassifikation der ISR er-
folgt meist nach Mehran et al. Die gegenwärtigen Behand-
lungsmöglichkeiten der ISR umfassen die erneute Ballon-
angioplastie, erneutes Stenting, den Cutting balloon, die di-
rekte Atherektomie, die Rotablation, die Brachytherapie und
die Medikamente freisetzenden Stents (DES). In randomisier-
ten Studien haben DES ihre Wirksamkeit in  der Reduktion der
binären Restenoserate bei De-novo-Stenosen bewiesen. In
multiplen (nicht randomisierten) Studen hat der Einsatz von
Sirolimus- und Paclitaxel-DES seine Sicherheit und Wirksam-
keit auch bei der Behandlung der ISR gezeigt. Die Verwendung
von DES in ISR führen zu einem neuen Problem: Der Einsatz
von ablativen Verfahren zur Behandlung der ISR nach DES soll-
te mit Bedacht geschehen. Die optimale Behandlung der ISR
nach DES ist unklar. Mehr Daten zum Einsatz einer erneuten
Implantation von DES bei ISR nach DES werden zeigen, ob die-
ses lästige Problem gelöst werden kann.
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DES have been effective in reducing binary restenosis in
de novo lesions in randomized controlled trials. The novel use
of DES to treat ISR has been shown to be safe and effective in
multiple studies involving sirolimus- and paclitaxel-eluting
stents. As DES implantation becomes more widespread, ISR in
DES is emerging as a new problem. The use of debulking tech-
niques to treat ISR in DES is to be cautioned against. In this
new era, the optimal treatment of this new problem is cur-
rently unknown. We await further data to see whether repeat
DES implantation may help solve this vexing clinical problem.
Schlüsselwörter: Medikamente freisetzende Stents · In-Stent-Restenose · Stents · Restenose · Sirolimus · 
Paclitaxel
Introduction
Coronary stent implantation reduces clinical and angio-
graphic restenosis compared to balloon angioplasty
alone and is currently performed in > 80% of percuta-
neous coronary interventions [1–3]. In-stent restenosis
(ISR), the most frequent late complication of stent im-
plantation, occurs in 10–80% of lesions treated in every-
day practice [4]. In 2001, it was estimated that 150,000
cases of ISR occurred in the USA alone [5]. On a world-
wide scale, the burden is much greater. The recent de-
velopment of drug-eluting stents (DES) has reduced the
incidence of stent-related restenosis to < 10% [6, 7], but
has not eliminated it completely.
Pathophysiology
Coronary stent implantation is inherently traumatic and
this trauma leads to a significant vessel wall “response
to injury” reaction that includes platelet activation and
adhesion to the vessel surface. Smooth muscle cells are
then activated, proliferate and mi-
grate to the intima. Excessive extra-
cellular matrix is produced and accu-
mulates. Neointimal formation is
principally composed of smooth mus-
cle cells and extracellular matrix. This
exaggerated neointimal formation
can lead to ISR.
Certain factors are known to in-
crease the risk of ISR. Lesion-related
factors include vessel diameter [8]
and prior restenosis [9]; procedure-
related specific factors include the
presence of residual dissection [10]
and length of stented vessel [11]; pa-
tient-related factors include diabetes
mellitus [12, 13]. In addition, multiple
genetic factors have been implicated
in the development of ISR.
Classification
Currently, the most widely used clas-
sification for ISR in bare metal stents
is that proposed by Mehran et al. [4].
The classification in based on the
length and pattern of the restenotic
lesion in relation to the stented por-
tion of the vessel. Four types of ISR
have been defined: (I) focal (≤ 10 mm
length); (II) diffuse (ISR > 10 mm
within the stent); (III) proliferative (ISR > 10 mm ex-
tending outside the stent); and (IV) occlusive ISR. Type
I is further subdivided into types IA–ID based on the
site of focal ISR in relation to the stent. This classifica-
tion has prognostic implications, as the incidence of tar-
get vessel revascularization (TVR) is related to the type
of ISR (Figure 1). Interestingly, with the introduction of
DES, the pattern of restenosis has changed into a pre-
dominantly focal one [14, 15].
Current Treatment Options
A variety of percutaneous techniques are currently
available to treat ISR. These include balloon angio-
plasty (POBA), cutting balloon angioplasty, rotational
coronary atherectomy, directional coronary atherec-
tomy (DCA), repeat bare stent implantation,
brachytherapy, and, more recently, DES. These vari-
ous techniques may be used either individually or in
combination.
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Incidence of ISR TVR for ISR in 
in bare stents bare stents 
(n = 293 lesions) at 1 year
Focal
42% 19.1%
Diffuse
21% 34.5%
Proliferative
30% 50.0%
Total occlusion
7% 83.4%
Figure 1. Classification and incidence of in-stent restenosis (ISR) in bare stents according to
Mehran et al. [4]. TVR: target vessel revascularization.
Abbildung 1. Klassifikation und Häufigkeit der In-Stent-Restenose unbeschichteter Edel-
stahlstents (nach Mehran et al. [4]).
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Balloon Angioplasty
POBA to treat ISR is the most appealing technique as it
is simple, cheap, universally available and requires no
new training. In the landmark angiographic study which
included 29% diffuse lesions, the angiographic re-
restenosis rate following POBA was only 22% [16]. The
authors noted that although the overall results in their
study were good, repeat intervention for diffuse and se-
vere ISR was associated with a high rate of recurrent
restenosis.
New Stent Implantation
New stent implantation for ISR was evaluated in a clin-
ical trial of 450 patients who were randomized to either
new stent implantation or POBA [17]. 60% of ISR were
diffuse lesions. Restenosis rates were similar (33% vs.
38%), as were rates of TVR (19.6% vs. 24.3%; p = 0.25),
indicating that systematic stenting was no better than
POBA in this setting.
Cutting Balloon Angioplasty
Cutting balloon angioplasty is a modality that relies on
microblades embedded on the surface of an angioplasty
balloon to incise the atherosclerotic plaque on balloon
inflation. In a retrospective study of matched lesion sub-
sets (30% diffuse lesions) comparing rotational coro-
nary atherectomy, POBA, stenting and cutting balloon
for the treatment of ISR, cutting balloon emerged as a
negative predictor of target lesion revascularization
(TLR; odds ratio 0.34 [0.16–0.73]; p = 0.001) [18]. The
angiographic re-restenosis rate amounted to 20%. TLR
at 9 months in this study was 15.8%, suggesting that cut-
ting balloon may be advantageous in this setting.
Rotational Coronary Atherectomy
The ARTIST study was a multicenter, randomized,
prospective European trial comparing usual-practice
POBA to rotablation followed by adjunctive low-pres-
sure (≤ 6 atm) POBA in 298 patients with diffuse ISR.
The results showed that in the long term, POBA was
better than rotablation. 6-month event-free survival in
the POBA group was 91.3% compared with 79.6% in
the rotablation group (p = 0.0052) [19]. However, a sub-
sequent trial known as the Rotational Atherectomy
Versus Balloon Angioplasty for Diffuse In-Stent
Restenosis (ROSTER) trial which was a single-center,
randomized trial comparing rotablation to POBA (both
with intravascular ultrasound [IVUS] guidance) in the
treatment of diffuse ISR in 200 patient, showed conflict-
ing results [20]. In the rotablation group (n = 100),
rotablation was followed by adjunctive balloon dilata-
tion at low pressure (4–6 atm). In the POBA group (n =
100), high-pressure (> 12 atm) balloon dilatation was
performed using an optimal-size balloon. The incidence
of TLR was 32% in the rotablation group and 45% in
the POBA group (p = 0.042), with a similar trend noted
in the angiographic substudy. The authors concluded
that rotablation resulted in less residual intimal hyper-
plasia, lower repeat stent use, and decreased TLR. Fur-
ther studies may clarify the role of rotational atherecto-
my in this setting.
Directional Coronary Atherectomy
In a nonrandomized study of 119 patients with ISR of
native coronary arteries, 58 underwent DCA and 61 un-
derwent rotablation for symptomatic coronary ISR [21].
Adjunctive balloon angioplasty at relatively high pres-
sures was performed in both groups. In both groups,
79% of patients had a diffuse pattern of ISR. Long-term
(12 month) results in the DCA group were superior as
reflected by a lower TLR (21% vs. 39%; p = 0.02) and
better event-free survival (72% vs. 56%; p = 0.03). Al-
though nonrandomized, this suggests a beneficial effect
of DCA over rotablation.
Other Techniques
Other debulking techniques such as excimer laser
cathether ablation (ELCA) have been studied [22, 23].
ELCA plus POBA was compared to POBA alone in a
study with 40% of diffuse ISR [22]. The results showed
no significant difference although there was a trend to-
ward a lower TVR in the ELCA group (21% vs. 38%; p
= 0.0823). A small angiographic study of exclusively dif-
fuse lesions treated with ELCA and POBA reported a
reocclusion rate of 46% [23].
Brachytherapy
Brachytherapy is, so far, the only proven therapy for
ISR. Randomized studies comparing brachytherapy to
placebo for the treatment of ISR have demonstrated
significant reductions in restenosis rates and in major
adverse cardiac event (MACE) rates (Table 1). Howev-
er, brachytherapy has limited availability, is costly, re-
quires training and additional personnel, and may call
for renovation of the catheterization laboratory in the
case of -radiation. Furthermore, potential side effects
of brachytherapy include late thrombosis [24], delayed
healing [25], the “black hole” phenomenon [26], and ge-
ographic miss [27] limiting the applicability of the tech-
nique.
A combination strategy of pretreatment with cut-
ting balloon angioplasty followed by g-brachytherapy
was investigated as a substudy of the SCRIPPS III Trial.
In their retrospective report, 76 patients received cut-
ting balloon angioplasty while 407 patients received
conventional percutaneous transluminal coronary an-
gioplasty (PTCA) before -brachytherapy. The groups
were reasonably matched for baseline characteristics.
TVR was similar in both groups (35.1% vs. 29.8%; p =
0.4) but was associated with less requirement for new
stents (11% vs. 22%; p = 0.02) [28].
Drug-Eluting Stent Implantation for In-Stent
Restenosis
Following on from the encouraging results obtained in
de novo lesions, there has been interest in the extension
of this application to ISR lesions. The use of DES to
treat ISR is immensely attractive. As mentioned above,
stent implantation is simple, requires no further train-
ing, and, most importantly, does not call for the complex
logistics of a brachytherapy unit. To date, however, clin-
ical experience has been limited to small groups of pa-
tients [29–34].
Sirolimus-Eluting Stents
Sirolimus or rapamycin, a natural macrocyclic lactone,
is a potent immunosuppressive agent. Sirolimus binds to
its cytosolic receptor, FK506-binding protein 12, and
this complex then inhibits a kinase called the mam-
malian target of rapamycin (mTOR) [35], which is a
component in a pathway that regulates cell cycle pro-
gression which ultimately induces cell cycle arrest in the
late G1 phase. It inhibits the proliferation of both rat
and human smooth muscle cells in vitro [36, 37] and re-
duces intimal thickening in models of vascular injury
[38]. Evidence that sirolimus may have an active role to
play in the treatment of ISR is further supported by a
study which demonstrated a robust upregulation of
FK506-binding protein 12 in atherectomy specimens of
ISR from human coronary arteries compared to control
specimens [39].
The efficacy of the sirolimus-coated Bx Velocity stent
(Cypher™, Cordis a Johnson and Johnson Company) in
preventing neointimal hyperplasia in stented de novo le-
sions was first demonstrated in the First in Man (FIM)
Trial [40, 41]. These findings have now been confirmed in
two further landmark trials, the RAVEL [42], and SIR-
IUS [6] trials. More recently, the RESEARCH Registry
comprising 508 consecutive de novo patients treated in
the real world with sirolimus-eluting stents (SES) report-
ed similar excellent results [43].
Rotterdam FIM. In the Rotterdam FIM Registry, 16
consecutive patients with severe recurrent ISR in a na-
tive coronary artery with objective evidence of ischemia
were included [32]. They were treated with at least one
18-mm SES. At 4-month angiographic follow-up, one
patient had suffered sudden death, while among the re-
maining 15 patients, three had recurrent ISR (20%).
São Paulo FIM. In the São Paulo FIM Registry, 25
consecutive patients with ISR in a native coronary
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Table 1. Randomized brachytherapy trials for in-stent restenosis. MACE: major adverse cardiac events.
Tabelle 1.  Randomisierte Brachytherapie-Studien zur In-Stent-Restenose: In allen Studien zeigte sich eine signifikante Reduktion der In-Stent-Re-
Restenose nach Brachytherapie.
Radiation Trial name Patients Lesion Restenosis p-value MACE (%) p-value
source (n) length rate 
(mm) (%)
Treated Placebo Treated Placebo
-radiation
90Sr/90Y START [54] 476 < 20 29 45 0.001 19 29 0.024
32P wire INHIBIT [55] 332 < 22 26 52 0.0001 15 31 0.006
90Y BETA WRIST [56] 50 < 47 34 71 0.001 34 76 0.001
-radiation
132Ir wire GAMMA-I [5] 252 < 45 32 55 0.01 28 44 0.02
GAMMA WRIST [57] 130 < 47 22 60 0.0001 35 68 < 0.001
SCRIPPS [58] 55 < 30 17 54 0.01 15 48 0.01
SCRIPPS 3 years [59] 55 < 30 33 64 < 0.05 23 55 0.01
Long WRIST [62] 120 36–80 45 73 < 0.05 42 63 < 0.05
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artery were treated with at least one 18-mm SES [31].
At 12-month angiographic follow-up, one patient had
ISR (4%).
SES versus Brachytherapy. To date, only one study
has been published comparing the results of SES im-
plantation versus vascular brachytherapy (VBT) for the
treatment of ISR [44]. This nonrandomized study com-
pared 43 patients treated with VBT against 44 patients
treated with SES. Baseline characteristics were similar
in both groups. During follow-up, three patients (7%)
died in the VBT group and none in the SES group. The
incidence of myocardial infarction was 2.3% in both
groups. TLR was performed in 11.6% of the VBT pa-
tients and 16.3% of the SES patients (p = NS). The 9-
month MACE-free survival was similar in both groups
(79.1% VBT vs. 81.5% SES; p = 0.8 by log rank). The
authors concluded that SES implantation was at least as
effective as VBT for the treatment of ISR.
SES for Post-Brachytherapy Failures. Post-brachy-
therapy failures, defined as the recurrence of ISR follow-
ing intracoronary brachytherapy to treat ISR, have a high
rate of recurrence and make up a small but significant
proportion of patients. In a small study of twelve patients
who received SES for the above indication, ten returned
for angiographic follow-up between 4–7 months post pro-
cedure and ISR was found in four patients (40%) [33]. In
addition, they were followed up clinically for 8.5 ± 4.5
months during which time seven of twelve remained
event-free (58%). Another study looked at the clinical
follow-up of 51 patients following repeated VBT for
failed VBT and reported that 71% of their patients were
event-free at 9 months [45]. To date, there have been no
head-to-head comparisons of SES versus VBT in failed
VBT patients, although the results from the two studies
cited appear to suggest that they are similar.
Paclitaxel-Eluting Stents
Paclitaxel, an antitumor agent used in the treatment of
ovarian and breast cancer, acts by binding to micro-
tubules and stabilizes their structure, thus enhancing
microtubule assembly, resulting in inhibition of cellu-
lar replication [46]. Cells remain viable; however, cell
processes dependent on microtubule turnover such as
mitosis, migration, endocytosis and secretion are in-
hibited. Thus, paclitaxel acts at two sites in the cell cy-
cle: the G2/M junction and the M/G0 junction. In vitro
studies have demonstrated that paclitaxel inhibits the
proliferation and migration of vascular smooth muscle
cells [47–50].
The efficacy of paclitaxel-eluting stents (TAXUS
NIRx™, Boston Scientific Corporation) for the treat-
ment of de novo lesions was demonstrated in the
TAXUS I and II Trials [51, 52]. These findings have
now been confirmed in the landmark trial, TAXUS IV
[7].
TAXUS III. The TAXUS III Trial was a single-
arm, two-center study of 28 patients with ISR of mean
lesion length 13.6 mm treated with TAXUS NIRx™
stents (Boston Scientific Corporation) [34]. 25 patients
completed angiographic follow-up at 6 months, with a
binary re-restenosis rate of 16%. TVR at 6 and 12
months was unchanged at 21.4%; similarly, MACE was
also unchanged between 6 and 12 months at 29%.
QuaDS-QP2 ISR. A negative study that deserves
mention is the first experience with the QuaDS-QP2
stent (Quanum Medical Corporation) of 15 consecu-
tive patients with ISR treated at two centers [53]. 
Although 6-month angiographic follow-up demon-
strated a restenosis rate of 13.3%, by 12 months this
had deteriorated markedly to 61.5%. TLR at 12 months
was 60%.
Table 2. Summary of published studies with drug-eluting stents (DES) for the treatment of bare metal stent in-stent restenosis (ISR). MACE: ma-
jor adverse cardiac events; N/A: not available; TLR: target lesion revascularization.
Tabelle 2. Zusammenfassung der bisher publizierten Daten für Medikamente freisetzende Stents zur Behandlung einer In-Stent-Restenose nach
Implantation eines unbeschichteten Edelstahlstents.
Rotterdam São Paulo RESEARCH-ISR SES for failed TAXUS III [34]
FIM [32] FIM [31] [44] brachytherapy [33]
DES Sirolimus Sirolimus Sirolimus Sirolimus Paclitaxel
Patients (n) 16 25 44 12 28
Diffuse disease (%) 81 68 58 75 64
Follow-up duration (months) 9 12 9 8.5 12
Re-restenosis rate [n (%)] 3/15 (20) 1/25 (4) N/A 4/10 (40) 4/25 (16)
TLR (%) 8.3 N/A 16.3 25.0 21.4
MACE (%) 18.7 N/A 18.5 41.6 29.0
Future Perspectives
In-Stent Restenosis in Drug-Eluting Stents
To date, DES trials have demonstrated that the resteno-
sis rate in DES ranges from 0 to 9% [6, 7] (Table 3).
While this number is a great improvement over the re-
sults seen with bare stents, it is certainly not negligible,
and as the use of DES increases worldwide, the opti-
mum treatment of this new problem will need to be de-
fined. Currently, there is no data on the best way to treat
ISR in DES. Possible options are:
(1) repeat DES implantation with the same DES;
(2) repeat DES implantation with a different DES – this
may prove beneficial if localized drug resistance to
the initial DES is suspected;
(3) another previously described method – possibly
brachytherapy;
(4) coronary artery bypass grafting, should the above
strategies fail.
The current practice at our institution is that 85% of
these lesions have been treated with repeat DES im-
plantation.
Debulking Techniques and DES. A note of caution
is warranted in relation to the application of debulking
techniques (rotablation, DCA, cutting balloon angio-
plasty) for the treatment of restenosis in DES. Most of
the stents have a polymer coating the stent struts. Dis-
ruption of the polymer may have unforeseen conse-
quences. First, this polymer layer may contain signifi-
cant drug reservoir that was not released during the ini-
tial eluting phase. Second, disruption of the polymer
may expose elements of the polymer to the systemic cir-
culation.
Of note, the type of ISR in DES has changed to a pre-
dominantly focal pattern. Between 84–100% of ISR have
been reported as predominantly focal (≤ 10 mm) [14, 15].
Whether the classification of Mehran et al. [4] remains
pertinent with regards to TLR remains to be seen.
Other Drug-Eluting Stents
Other DES are currently in various phases of develop-
ment. Their utility in the treatment of simple de novo le-
sions must first be proven before any attempt is made to
extend their application to the treatment of ISR. Drugs
that appear promising currently include everolimus
(Guidant Corporation), ABT-578 (Abbott Vascular and
Medtronic), and biolimus (Terumo and Biosensors).
This list is by no means exhaustive, and many more
drugs will be tested in the future to determine their abil-
ity to reduce the incidence of ISR.
Conclusion
ISR in bare stents remains a major therapeutic hurdle as
long as bare stents are implanted. Brachytherapy is the
only proven tool, but its application is a logistic night-
mare. Preliminary results available so far indicate that
DES, in particular Cypher™ and TAXUS™, are safe
and feasible alternatives to treat ISR. The increasing
use of DES to treat de novo lesions has introduced a
new therapeutic challenge with the development of ISR
in DES albeit with a much lower incidence than seen
with bare stents. In this new era, the optimal treatment
of this new problem is currently unknown. We await fur-
ther data to see whether repeat DES implantation may
help solve this vexing clinical problem.
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Table 3. Incidence of restenoses in major drug-eluting stent (DES) trials. MACE: major adverse cardiac events; N/A: not available; TLR: target le-
sion revascularization.
Tabelle 3. Häufigkeit einer Restenose in den größeren Studien mit Medikamente freisetzenden Stents.
Study SIRIUS [6] TAXUS IV [7] E-SIRIUS [60] ASPECT [61] RESEARCH [43]
Drug Sirolimus Paclitaxel Sirolimus Paclitaxel Sirolimus
Study design Randomized, single Randomized, single Randomized, single Randomized, dose- Consecutive registry,
de novo lesion de novo lesion de novo lesion finding, single de novo all comers de novo 
lesion, high dose lesions
Patients in DES group (n) 533 662 175 60 508
Follow-up duration (months) 9 9 9 6 12
Follow-up type Angiographic and Angiographic and Angiographic and Angiographic and Clinical
clinical clinical clinical clinical
Restenosis rate (%) 8.9 7.9 5.9 4.0 N/A
TLR (%) 4.1 3.0 4.0 1.7 ~ 3.5
MACE (%) 8.6 7.6 8.0 4.0 9.7
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